These findings suggest that HBV-mediated HCC-promoting properties could be attributed to the miR-155-induced silencing of ZHX2, and they suggest a novel therapy for HBV-related HCC by targeting the miR-155 pathway. The gene discussed is ZHX2; the disease is hepatocellular carcinoma.